GENFIT Share Price Xetra
Stocks
XUP
FR0004163111
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.30 EUR | -0.45% |
|
-2.21% | +149.77% |
| 07-03 | Genfit soars on news of U.S. reimbursement for a product |  |
| 07-03 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
| Market Cap | 645M 738M 595M 549M 1.03B 71.11B 1.06B 7.12B 2.8B 34.83B 2.77B 2.71B 120B | P/E 2026 * |
67.8x | P/E 2027 * | 85.7x |
|---|---|---|---|---|---|
| Enterprise Value | 594M 680M 548M 505M 953M 65.48B 974M 6.55B 2.58B 32.07B 2.55B 2.5B 110B | EV / Sales 2026 * |
5.93x | EV / Sales 2027 * | 4.67x |
| Free-Float |
86.88% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -0.45% | ||
| 1 week | -2.21% | ||
| Current month | +52.17% | ||
| 1 month | +52.17% | ||
| 3 months | +44.88% | ||
| 6 months | +141.82% | ||
| Current year | +149.77% |
| 1 week | 13.14 |  | 13.46 |
| 1 month | 13.14 | | 13.6 |
| Current year | 5.2 | | 13.6 |
| 1 year | 3.19 | | 13.6 |
| 3 years | 3.19 | | 13.6 |
| 5 years | 3.19 | | 13.6 |
| 10 years | 3.19 | | 13.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 58 | 15/09/2019 |
Thomas Baetz
DFI | Director of Finance/CFO | 52 | 21/04/2021 |
Pejvack Motlagh
CTO | Chief Tech/Sci/R&D Officer | - | 26/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 15/06/2017 | |
| Director/Board Member | 54 | 14/09/1999 | |
| Director/Board Member | 58 | 15/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.45% | -2.21% | - | - | 738M | |
| +3.90% | -0.39% | +376.72% | +599.59% | 39.58B | |
| -1.70% | +4.46% | +7.46% | +57.67% | 34.69B | |
| -2.01% | -0.76% | +26.35% | -6.83% | 34.42B | |
| +0.06% | +0.34% | +2.32% | +29.30% | 27.11B | |
| +0.46% | -3.49% | - | - | 16.21B | |
| -0.04% | -0.09% | +68.48% | +117.39% | 15.36B | |
| +1.12% | +1.91% | +15.90% | +19.65% | 14.05B | |
| 0.00% | +1.36% | +15.74% | -30.62% | 13.02B | |
| -0.08% | -3.01% | +1,271.69% | +649.69% | 11.76B | |
| Average | +0.13% | +0.04% | +223.08% | +179.48% | 22.91B | |
| Weighted average by Cap. | +0.24% | +0.36% | +171.43% | +187.42% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 100M 115M 92.46M 85.22M 161M 11.04B 164M 1.11B 435M 5.41B 431M 421M 18.62B | 124M 142M 114M 106M 199M 13.67B 203M 1.37B 538M 6.69B 533M 521M 23.05B |
| Net income | 22.88M 26.18M 21.11M 19.46M 36.68M 2.52B 37.49M 252M 99.25M 1.23B 98.32M 96.16M 4.25B | 6.8M 7.78M 6.27M 5.78M 10.9M 749M 11.14M 75M 29.5M 367M 29.22M 28.58M 1.26B |
| Net Debt | -51.12M -58.49M -47.17M -43.48M -81.95M -5.63B -83.77M -564M -222M -2.76B -220M -215M -9.5B | -66.17M -75.72M -61.06M -56.28M -106M -7.29B -108M -730M -287M -3.57B -284M -278M -12.29B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/07/26 | €13.30 | -0.45% | 469 |
| 13/07/26 | €13.36 | -1.76% | 518 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GNFT Stock
- XUP Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
